ALB and neoplasm: In our study, we detailed the development of what we believe to be a novel Flt3L-based therapeutic molecule, Alb-Flt3L, that has enhanced pharmacokinetic properties, including LN and tumor targeting and enhanced half-life compared with Flt3L.